Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Active Not Recruiting NCT06547385

Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer

Conditions: Colorectal Cancer

Sex: All

Ages: 20 Years – N/A

Healthy volunteers: No

Phase: PHASE1

Enrollment: 40

Sponsor: Ono Pharmaceutical Co., Ltd.

Location: National Cancer Center Hospital East Kashiwa-shi Chiba

Summary

To evaluate the tolerability and safety of combination of ONO-4578 and ONO-4538 and the standard of care XELOX + bevacizumab or the safety of combination of ONO-4578 and ONO-4538 and the standard of care FOLFOX + bevacizumab as first-line therapy in patients with unresectable, advanced, or recurrent colorectal cancer.

Eligibility Criteria

Inclusion Criteria: * Unresectable colorectal cancer * Life expectancy of at least 3 months * Patients with ECOG performance status 0 or 1 Exclusion Criteria: * Patients with severe complication * Patients are unable to swallow oral medications

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06547385). StuddyBuddy aggregates publicly available trial information.